CD33 rs3865444 as a risk factor for Parkinson's disease
Copyright © 2021 Elsevier B.V. All rights reserved..
BACKGROUND: Alzheimer's (AD) and Parkinson's diseases (PD) share a few elements of their clinical, pathological and genetic backgrounds. The CD33 rs3865444 has emerged as a strong genetic locus associated with AD through genome-wide association study (GWAS). However, little is known for its role in PD.
OBJECTIVE: To assess the role of CD33 rs3865444 on PD risk.
METHODS: We genotyped 358 patients with PD and 358 healthy controls for theCD33 rs3865444. Odds ratios (ORs) with the respective 95% confidence intervals (CIs)], were calculated with the SNPStats software, assuming five genetic models (co-dominant, dominant, recessive, over-dominant and log-additive), with the G allele as the reference allele.
RESULTS: The CD33 rs3865444 was associated with decreased PD risk in the dominant [GG vs GT + TT; OR (95% CI) = 0.61 (0.45-0.82), p = 0.001], the over-dominant [GG + TT vs GT; OR (95% CI) = 0.65 (0.48-0.89), p = 0.0061], log-additive [OR (95% CI) = 0.67 (0.52-0.86), p = 0.0014], and co-dominant [with overall p = 0.0043, and OR (95% CI) = 0.62 (0.45-0.84) for the TG genotype compared to the GG], modes of inheritance.
CONCLUSIONS: The CD33 rs3865444 is associated with decreased PD risk, and larger studies investigating the role of CD33 rs3865444 on PD are needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:748 |
|---|---|
| Enthalten in: |
Neuroscience letters - 748(2021) vom: 23. März, Seite 135709 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Siokas, Vasileios [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CD33 |
|---|
| Anmerkungen: |
Date Completed 03.06.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neulet.2021.135709 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321418336 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321418336 | ||
| 003 | DE-627 | ||
| 005 | 20231225175750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neulet.2021.135709 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321418336 | ||
| 035 | |a (NLM)33582190 | ||
| 035 | |a (PII)S0304-3940(21)00087-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Siokas, Vasileios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CD33 rs3865444 as a risk factor for Parkinson's disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.06.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Alzheimer's (AD) and Parkinson's diseases (PD) share a few elements of their clinical, pathological and genetic backgrounds. The CD33 rs3865444 has emerged as a strong genetic locus associated with AD through genome-wide association study (GWAS). However, little is known for its role in PD | ||
| 520 | |a OBJECTIVE: To assess the role of CD33 rs3865444 on PD risk | ||
| 520 | |a METHODS: We genotyped 358 patients with PD and 358 healthy controls for theCD33 rs3865444. Odds ratios (ORs) with the respective 95% confidence intervals (CIs)], were calculated with the SNPStats software, assuming five genetic models (co-dominant, dominant, recessive, over-dominant and log-additive), with the G allele as the reference allele | ||
| 520 | |a RESULTS: The CD33 rs3865444 was associated with decreased PD risk in the dominant [GG vs GT + TT; OR (95% CI) = 0.61 (0.45-0.82), p = 0.001], the over-dominant [GG + TT vs GT; OR (95% CI) = 0.65 (0.48-0.89), p = 0.0061], log-additive [OR (95% CI) = 0.67 (0.52-0.86), p = 0.0014], and co-dominant [with overall p = 0.0043, and OR (95% CI) = 0.62 (0.45-0.84) for the TG genotype compared to the GG], modes of inheritance | ||
| 520 | |a CONCLUSIONS: The CD33 rs3865444 is associated with decreased PD risk, and larger studies investigating the role of CD33 rs3865444 on PD are needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CD33 | |
| 650 | 4 | |a Genetics | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a Single nucleotide polymorphism | |
| 650 | 4 | |a rs3865444 | |
| 650 | 7 | |a CD33 protein, human |2 NLM | |
| 650 | 7 | |a Sialic Acid Binding Ig-like Lectin 3 |2 NLM | |
| 700 | 1 | |a Arseniou, Stylianos |e verfasserin |4 aut | |
| 700 | 1 | |a Aloizou, Athina-Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Tsouris, Zisis |e verfasserin |4 aut | |
| 700 | 1 | |a Liampas, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Sgantzos, Markos |e verfasserin |4 aut | |
| 700 | 1 | |a Liakos, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Bogdanos, Dimitrios P |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjigeorgiou, Georgios M |e verfasserin |4 aut | |
| 700 | 1 | |a Dardiotis, Efthimios |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuroscience letters |d 1975 |g 748(2021) vom: 23. März, Seite 135709 |w (DE-627)NLM000386529 |x 1872-7972 |7 nnns |
| 773 | 1 | 8 | |g volume:748 |g year:2021 |g day:23 |g month:03 |g pages:135709 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neulet.2021.135709 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 748 |j 2021 |b 23 |c 03 |h 135709 | ||